Developer docs
API playgroundTry for free, no card

Search company profiles

Lumen Bioscience

Full company profile

uuid000034j

Namestring
Lumen Bioscience
Legal namestring
Lumen Bioscience, Inc.
Websiteurl
lumen.bio
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Lumen Bioscience is a privately held, clinical-stage biopharmaceutical company headquartered in Seattle that develops and manufactures oral biologic drug candidates using a proprietary spirulina-based biomanufacturing platform. Founded in 2017, the company was the first to successfully engineer Arthrospira platensis (edible blue-green algae) to express therapeutic proteins, a breakthrough that had eluded researchers for decades and is protected by 34 issued patents with 24 pending. The platform requires only water, salt, CO₂, and light for production, eliminates the need for sterility or complex downstream purification, and delivers therapeutic proteins at costs two to three orders of magnitude lower than traditional E. coli, CHO cell, or yeast biomanufacturing systems. Production is conducted at a fully integrated cGMP facility in Seattle with capacity of 15+ kg of GMP drug substance per week.

The company's pipeline includes seven candidates across infectious disease, metabolic disease, nephrology, gastroenterology, and global health. Lead program LMN-201, an oral biologic cocktail for C. difficile infection, is in Phase 2/3 (RePreve Trial) and demonstrated 100% initial clinical cure (21/21 patients) with 4.76% recurrence in its April 2025 sentinel cohort, materially outperforming historical standard-of-care and bezlotoxumab benchmarks; full Phase 3 results are expected in June 2026. LMN-801, an oral hormone protein for weight loss, is in Phase 2. Additional programs include an oral oxalate-degradation enzyme (Phase 2/3 ready), an IBD biologic (preclinical), an oral gastroenteritis antibody cocktail (Phase 1), an intranasal respiratory virus biologic (Phase 1), and an intranasal malaria vaccine (preclinical).

Lumen has raised over $185 million to date through a mix of equity and non-dilutive funding from the U.S. Department of Defense, NIH/NIAID, the Bill & Melinda Gates Foundation, CARB-X, MTEC, and venture capital investors. The company is pre-revenue, generates no commercial product sales, and is building commercial infrastructure for a U.S.-first launch followed by global rollout. Its go-to-market strategy blends eventual direct sales into hospital and retail pharmacy channels with potential out-licensing transactions, as indicated by CEO-disclosed inbound licensing interest from pharma companies for its C. difficile and weight loss candidates.

Short descriptiontext

Lumen Bioscience is a Seattle-based clinical-stage biotech that engineers spirulina algae to produce oral biologic drugs at 100–1000x lower cost than traditional biomanufacturing. It serves patients with C. difficile, obesity, IBD, kidney stones, gastroenteritis, respiratory viruses, and malaria across a seven-program pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral biologic drugs, spirulina biomanufacturing, therapeutic proteins, clinical-stage biopharmaceuticals, biologic vaccine candidates
Industry2 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Sales
TypeOne Time License
Description

The company is developing multiple biologic drug candidates across clinical pipeline. Once approved, products will be commercialized through pharmaceutical distribution channels. Lead program LMN-201 targets C. difficile infection with Phase 2/3 ongoing. Other programs include weight loss (LMN-801), IBD, oxalate degradation, gastroenteritis, viral respiratory infections, and malaria.

lumen.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lumen Bioscience discovers, develops, and manufactures biologic drug and vaccine candidates using a proprietary spirulina (edible blue-green algae) biomanufacturing platform. The company engineers Arthrospira platensis to express therapeutic proteins, enabling oral biologic delivery at costs two to three orders of magnitude lower than traditional biomanufacturing. Its clinical pipeline targets C. difficile infection, obesity, IBD, kidney stones, gastroenteritis, viral respiratory infections, and malaria.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% initial C. difficile clinical cure rate (21/21 patients) in Phase 2/3 RePreve Trial sentinel cohort
+3 more records
Product overview1 text field

Lumen Bioscience is a drug development company with a proprietary biomanufacturing platform using engineered spirulina (edible blue-green algae) to produce therapeutic proteins. The platform enables oral delivery of biologics at significantly reduced costs. The company's core pipeline includes: LMN-201 (Phase 2/3) - oral biologic cocktail for C. difficile infection; LMN-801 (Phase 2) - oral hormone protein for weight loss; oxalate degradation product (Phase 2/3 ready) - enzyme supplement for kidney stone prevention; IBD product (preclinical) - oral biologic for Crohn's disease and ulcerative colitis; gastroenteritis antibody cocktail (Phase 1); viral respiratory infections intranasal biologic (Phase 1); and malaria intranasal vaccine (preclinical). All products are developed using the spirulina-based manufacturing platform.

Product and service1 record
1LMN-201
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with scientific advisors including Jim Roberts, Co-Founder who was Director in the Basic Sciences Division. Co-inventor of mammalian cell transformation technology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research partner with multiple collaborations. Located nearby in Seattle. Scientific advisors include experts from UW School of Medicine in gastroenterology, metabolism, and nephrology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaborator in pipeline programs, particularly in the C. difficile program shown in pipeline with Rockefeller University logo.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration as shown in pipeline partners section, potentially related to metabolic disease/weight loss programs.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration in protein engineering and design, leveraging advanced computational methods for therapeutic protein development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaborator in veterinary applications and potential animal health uses of the platform technology.

7Monash University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International academic research collaborator in biotechnology and biomedical research.

lumen.bio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration including scientific advisor Jim Nataro, Professor and Chair of Pediatrics, involved in global health and infectious disease research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Massachusetts biotech industry association partnership supporting biotech ecosystem and collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Protalix is a clinical-stage company that manufactures therapeutic proteins using a plant-cell-based (carrot/chemically-induced) expression system. It is the most direct peer to Lumen's plant-based biologic manufacturing approach, sharing the core thesis that non-mammalian hosts can dramatically reduce cost and complexity of biologic production.

TypeDirect peer
Description

Seres is a microbiome therapeutics company whose VOWST was the first FDA-approved oral microbiome therapeutic for prevention of recurrent C. difficile infection. It is a direct competitor to Lumen's LMN-201 in the CDI recurrence setting and operates in the same clinical and commercial pathway.

TypeDirect peer
Description

Vedanta is developing defined bacterial consortia (VE303) for recurrent C. difficile infection, in direct competition with Lumen's LMN-201. Both companies are clinical-stage and target CDI recurrence, an indication with $5-8B in U.S. annual healthcare costs.

TypeEmerging player
Description

Novavax uses a protein-based nanoparticle platform to produce recombinant vaccines, sharing Lumen's strategy of producing complex protein therapeutics in non-mammalian systems for infectious disease indications. Both companies emphasize cost-effective, scalable production for global vaccine markets.

TypeEmerging player
Description

Ginkgo Bioworks is a synthetic biology platform company that engineers microorganisms (including algae) for industrial bioproduction. While broader in scope, it shares Lumen's strategy of programming non-mammalian organisms to produce high-value biological products.

TypeEmerging player
Description

Absci is an AI-driven generative biology company focused on designing and producing novel therapeutic antibodies and biologic drugs. It shares Lumen's emphasis on computational protein engineering and offers an alternative platform for low-cost biologic development.

TypeEmerging player
Description

InVitria develops recombinant protein production technologies and cell culture media components for biomanufacturing. It overlaps with Lumen's bioprocess technology and consumables theme, though focused on traditional mammalian cell culture vs. Lumen's spirulina approach.

TypeBroad incumbent
Description

Amgen is a global biopharma leader in biologic drug manufacturing and antibody therapeutics, with a broad infectious disease and inflammation portfolio. It is a broad incumbent that competes with Lumen in commercial-stage biologics and has partnered with Lumen scientific advisors.

TypeBroad incumbent
Description

Genentech pioneered recombinant antibody manufacturing and remains the global leader in monoclonal antibody therapeutics, including treatments for CDI-associated inflammation and IBD. It is a broad incumbent that competes in Lumen's target therapeutic areas using traditional CHO-based manufacturing.

TypeBroad incumbent
Description

BioMarin is a clinical and commercial-stage biologics manufacturer focused on rare and serious diseases, using mammalian and microbial expression systems. It is a broad incumbent in specialty biologics and represents the kind of large biopharma partner that could license Lumen's platform or individual programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles27 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lumen Bioscience

Biopharmaceuticalslumen.bio

Lumen Bioscience is a Seattle-based clinical-stage biotech that engineers spirulina algae to produce oral biologic drugs at 100–1000x lower cost than traditional biomanufacturing. It serves patients with C. difficile, obesity, IBD, kidney stones, gastroenteritis, respiratory viruses, and malaria across a seven-program pipeline.

What Lumen Bioscience does

Lumen Bioscience is a privately held, clinical-stage biopharmaceutical company headquartered in Seattle that develops and manufactures oral biologic drug candidates using a proprietary spirulina-based biomanufacturing platform. Founded in 2017, the company was the first to successfully engineer Arthrospira platensis (edible blue-green algae) to express therapeutic proteins, a breakthrough that had eluded researchers for decades and is protected by 34 issued patents with 24 pending. The platform requires only water, salt, CO₂, and light for production, eliminates the need for sterility or complex downstream purification, and delivers therapeutic proteins at costs two to three orders of magnitude lower than traditional E. coli, CHO cell, or yeast biomanufacturing systems. Production is conducted at a fully integrated cGMP facility in Seattle with capacity of 15+ kg of GMP drug substance per week.

The company's pipeline includes seven candidates across infectious disease, metabolic disease, nephrology, gastroenterology, and global health. Lead program LMN-201, an oral biologic cocktail for C. difficile infection, is in Phase 2/3 (RePreve Trial) and demonstrated 100% initial clinical cure (21/21 patients) with 4.76% recurrence in its April 2025 sentinel cohort, materially outperforming historical standard-of-care and bezlotoxumab benchmarks; full Phase 3 results are expected in June 2026. LMN-801, an oral hormone protein for weight loss, is in Phase 2. Additional programs include an oral oxalate-degradation enzyme (Phase 2/3 ready), an IBD biologic (preclinical), an oral gastroenteritis antibody cocktail (Phase 1), an intranasal respiratory virus biologic (Phase 1), and an intranasal malaria vaccine (preclinical).

Lumen has raised over $185 million to date through a mix of equity and non-dilutive funding from the U.S. Department of Defense, NIH/NIAID, the Bill & Melinda Gates Foundation, CARB-X, MTEC, and venture capital investors. The company is pre-revenue, generates no commercial product sales, and is building commercial infrastructure for a U.S.-first launch followed by global rollout. Its go-to-market strategy blends eventual direct sales into hospital and retail pharmacy channels with potential out-licensing transactions, as indicated by CEO-disclosed inbound licensing interest from pharma companies for its C. difficile and weight loss candidates.

Lumen Bioscience firmographics

Firmographics
Name
Lumen Bioscience
Legal name
Lumen Bioscience, Inc.
Website
https://lumen.bio
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Lumen Bioscience is a Seattle-based clinical-stage biotech that engineers spirulina algae to produce oral biologic drugs at 100–1000x lower cost than traditional biomanufacturing. It serves patients with C. difficile, obesity, IBD, kidney stones, gastroenteritis, respiratory viruses, and malaria across a seven-program pipeline.
Ownership category
akta.pro rank

Lumen Bioscience industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oral biologic drugs
  • Spirulina biomanufacturing
  • Therapeutic proteins
  • Clinical-stage biopharmaceuticals
  • Biologic vaccine candidates

Where Lumen Bioscience is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lumen Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Sales: The company is developing multiple biologic drug candidates across clinical pipeline. Once approved, products will be commercialized through pharmaceutical distribution channels. Lead program LMN-201 targets C. difficile infection with Phase 2/3 ongoing. Other programs include weight loss (LMN-801), IBD, oxalate degradation, gastroenteritis, viral respiratory infections, and malaria.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Lumen Bioscience product offering

Product offering

Core offering

Lumen Bioscience discovers, develops, and manufactures biologic drug and vaccine candidates using a proprietary spirulina (edible blue-green algae) biomanufacturing platform. The company engineers Arthrospira platensis to express therapeutic proteins, enabling oral biologic delivery at costs two to three orders of magnitude lower than traditional biomanufacturing. Its clinical pipeline targets C. difficile infection, obesity, IBD, kidney stones, gastroenteritis, viral respiratory infections, and malaria.

Product overview

Lumen Bioscience is a drug development company with a proprietary biomanufacturing platform using engineered spirulina (edible blue-green algae) to produce therapeutic proteins. The platform enables oral delivery of biologics at significantly reduced costs. The company's core pipeline includes: LMN-201 (Phase 2/3) - oral biologic cocktail for C. difficile infection; LMN-801 (Phase 2) - oral hormone protein for weight loss; oxalate degradation product (Phase 2/3 ready) - enzyme supplement for kidney stone prevention; IBD product (preclinical) - oral biologic for Crohn's disease and ulcerative colitis; gastroenteritis antibody cocktail (Phase 1); viral respiratory infections intranasal biologic (Phase 1); and malaria intranasal vaccine (preclinical). All products are developed using the spirulina-based manufacturing platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • LMN-201

Quantifiable outcome

  • 100% initial C. difficile clinical cure rate (21/21 patients) in Phase 2/3 RePreve Trial sentinel cohort
  • +3 more outcomes

Companies that use Lumen Bioscience

Customer profile

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Lumen Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lumen Bioscience partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Fred Hutchinson Cancer Research CentercoreStrategic or Co-development PartnerResearch collaboration with scientific advisors including Jim Roberts, Co-Founder who was Director in the Basic Sciences Division. Co-inventor of mammalian cell transformation technology.
  • University of WashingtonmajorStrategic or Co-development PartnerAcademic research partner with multiple collaborations. Located nearby in Seattle. Scientific advisors include experts from UW School of Medicine in gastroenterology, metabolism, and nephrology.
  • Rockefeller UniversitymajorStrategic or Co-development PartnerResearch collaborator in pipeline programs, particularly in the C. difficile program shown in pipeline with Rockefeller University logo.
  • Novo NordiskmajorStrategic or Co-development PartnerResearch collaboration as shown in pipeline partners section, potentially related to metabolic disease/weight loss programs.
  • Institute for Protein Design (UW)majorStrategic or Co-development PartnerCollaboration in protein engineering and design, leveraging advanced computational methods for therapeutic protein development.
  • Tufts University (Cummings School of Veterinary Medicine)minorStrategic or Co-development PartnerResearch collaborator in veterinary applications and potential animal health uses of the platform technology.
  • Monash UniversityminorStrategic or Co-development PartnerInternational academic research collaborator in biotechnology and biomedical research.
  • University of VirginiaminorStrategic or Co-development PartnerResearch collaboration including scientific advisor Jim Nataro, Professor and Chair of Pediatrics, involved in global health and infectious disease research.
  • MassBiominorStrategic or Co-development PartnerMassachusetts biotech industry association partnership supporting biotech ecosystem and collaboration.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Lumen Bioscience competitors and assessment

Company assessment

Direct peers

  • Protalix BioTherapeutics: Protalix is a clinical-stage company that manufactures therapeutic proteins using a plant-cell-based (carrot/chemically-induced) expression system. It is the most direct peer to Lumen's plant-based biologic manufacturing approach, sharing the core thesis that non-mammalian hosts can dramatically reduce cost and complexity of biologic production.
  • Seres Therapeutics: Seres is a microbiome therapeutics company whose VOWST was the first FDA-approved oral microbiome therapeutic for prevention of recurrent C. difficile infection. It is a direct competitor to Lumen's LMN-201 in the CDI recurrence setting and operates in the same clinical and commercial pathway.
  • Vedanta Biosciences: Vedanta is developing defined bacterial consortia (VE303) for recurrent C. difficile infection, in direct competition with Lumen's LMN-201. Both companies are clinical-stage and target CDI recurrence, an indication with $5-8B in U.S. annual healthcare costs.

Emerging players

  • Novavax: Novavax uses a protein-based nanoparticle platform to produce recombinant vaccines, sharing Lumen's strategy of producing complex protein therapeutics in non-mammalian systems for infectious disease indications. Both companies emphasize cost-effective, scalable production for global vaccine markets.
  • Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology platform company that engineers microorganisms (including algae) for industrial bioproduction. While broader in scope, it shares Lumen's strategy of programming non-mammalian organisms to produce high-value biological products.
  • Absci: Absci is an AI-driven generative biology company focused on designing and producing novel therapeutic antibodies and biologic drugs. It shares Lumen's emphasis on computational protein engineering and offers an alternative platform for low-cost biologic development.
  • InVitria: InVitria develops recombinant protein production technologies and cell culture media components for biomanufacturing. It overlaps with Lumen's bioprocess technology and consumables theme, though focused on traditional mammalian cell culture vs. Lumen's spirulina approach.

Broad incumbents

  • Amgen: Amgen is a global biopharma leader in biologic drug manufacturing and antibody therapeutics, with a broad infectious disease and inflammation portfolio. It is a broad incumbent that competes with Lumen in commercial-stage biologics and has partnered with Lumen scientific advisors.
  • Genentech (Roche): Genentech pioneered recombinant antibody manufacturing and remains the global leader in monoclonal antibody therapeutics, including treatments for CDI-associated inflammation and IBD. It is a broad incumbent that competes in Lumen's target therapeutic areas using traditional CHO-based manufacturing.
  • BioMarin Pharmaceutical: BioMarin is a clinical and commercial-stage biologics manufacturer focused on rare and serious diseases, using mammalian and microbial expression systems. It is a broad incumbent in specialty biologics and represents the kind of large biopharma partner that could license Lumen's platform or individual programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lumen Bioscience social profiles

Digital presence

Lumen Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lumen Bioscience leadership team

Management profile

Number of profiles

Profiles27 records

Lumen Bioscience funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lumen Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lumen Bioscience

What does Lumen Bioscience do?

Lumen Bioscience discovers, develops, and manufactures biologic drug and vaccine candidates using a proprietary spirulina (edible blue-green algae) biomanufacturing platform. The company engineers Arthrospira platensis to express therapeutic proteins, enabling oral biologic delivery at costs two to three orders of magnitude lower than traditional biomanufacturing. Its clinical pipeline targets C. difficile infection, obesity, IBD, kidney stones, gastroenteritis, viral respiratory infections, and malaria.

Is Lumen Bioscience a public or private company?

Lumen Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lumen Bioscience founded?

Lumen Bioscience was founded in 2017. It employs 101 to 250 people.

Where is Lumen Bioscience based?

Lumen Bioscience is headquartered in Seattle, United States, in the North America region.

How does Lumen Bioscience make money?

One revenue line is on record: biopharmaceutical Product Sales.

Who are Lumen Bioscience's main competitors?

Direct peers on record are Protalix BioTherapeutics, Seres Therapeutics and Vedanta Biosciences. Emerging players are Novavax, Ginkgo Bioworks, Absci and InVitria. Broad incumbents are Amgen, Genentech (Roche) and BioMarin Pharmaceutical.

Does Lumen Bioscience have an API?

No public API is recorded for Lumen Bioscience.

What industry is Lumen Bioscience in?

Lumen Bioscience's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLumens Bios Agrees to Acquire 34% Stake in Polaris Uno Through Shares, Convertible BondsLumens Bios agreed to acquire a 34% stake in Polaris Uno through share and convertible bond purchase contracts. The interest includes 1,900,000 voting shares (11.02% of outstanding) and convertible bonds for 6,000,000 shares, with closing scheduled for December 11, 2026.EIN PresswireLumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)Lumen Bioscience reported positive Phase 2 results from the RePreve trial of oral LMN-201 for C. difficile infection, showing a global cure rate of 83.3% versus 36.4% with placebo. The treatment plus standard-of-care antibiotics reduced recurrence to 9.1% versus 55.6% with placebo. Results will be presented at IDWeek 2026.PR NewswireLumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial (LMN-201 for C. difficile Infection)Lumen Bioscience reported positive Phase 2 results from the RePreve trial of oral LMN-201 for C. difficile infection, showing a global cure rate of 83.3% versus 36.4% for placebo. The treatment plus standard-of-care antibiotics reduced recurrence by six-fold (9.1% versus 55.6%). Results will be presented at IDWeek 2026.BioCenturyThe future of biotech is preventive — and globalThis is an analytical commentary arguing that two structural shifts are reshaping the biotech industry's trajectory: growth moving from U.S.-centric blockbuster economics toward global markets, and from reactive treatment toward large-scale preventive medicine. The article cites Deloitte data showing biopharma's internal rate of return from drug discovery fell to just 1.2% in 2022, contrasting this with Pfizer's $55 billion revenue in 2021 from volume-priced products Comirnaty and Paxlovid as evidence that accessible pricing can unlock larger markets. The author, Lumen Bioscience's co-founder and CEO, argues that the winning strategies for the next wave of biotechs will favor companies with technologies able to manufacture at scale and lower price points to serve the global middle class, citing GLP-1 drug makers Novo Nordisk and Eli Lilly as examples.Contagion LiveLMN-201 Fast Tracked by FDA as a Potential Breakthrough Treatment for C diff InfectionLumen Bioscience announced that the US Food and Drug Administration (FDA) granted Fast Track Designation for LMN-201, the company's investigational oral biologic drug for treating and preventing Clostridioides difficile infection (CDI). The FDA had previously approved a phase 2/3 study, which Lumen intends to enroll approximately 375 patients across the United States later this year. LMN-201 is a capsule containing four therapeutic proteins that neutralize both the C diff bacterium and the toxin causing its virulence, intended for use alongside standard-of-care antibiotics.Contagion LiveInvestigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary CohortLumen Bioscience reported that its investigational oral biologic LMN-201 achieved a 100% initial clinical cure rate (21 of 21 patients) in the sentinel cohort of the RePreve clinical trial for Clostridioides difficile infection (CDI), significantly outperforming the 80% cure rate observed in historical controls from the MODIFY I/II studies. Only 1 of 21 patients (4.76%) experienced CDI recurrence within 28 days, compared with 26% recurrence with standard of care alone and 14% with bezlotoxumab. The company has now initiated part B of the trial, a pivotal randomized, double-blind, placebo-controlled study enrolling approximately 350 patients across US research centers with an extended dosing period of approximately 70 days.EurekAlert!Spirulina under the microscope (IMAGE)Lumen Bioscience researchers engineered spirulina to biomanufacture an enzyme that destroys methanogens in cows' rumen within minutes. The enzyme-containing spirulina is so effective that a tiny amount in a cow's diet makes them methanogen-free.LumenLumen BioscienceLumen Bioscience is utilizing a patented technology that employs food-grade spirulina algae to produce therapeutic proteins for biologic drugs. This platform aims to reduce development costs and increase scalability by using simple inputs like water, light, and CO2 to generate high-yield protein expressions.PR NewswireLumen Bioscience Expands Board and Leadership Team to Advance Clinical Pipeline of Novel Oral BiologicsLumen Bioscience announced leadership expansions and board additions to support its clinical pipeline of oral biologics, following a $30 million Series C financing extension led by WestRiver Group. The company also highlighted the success of its investigational drug LMN-201 for recurrent C. difficile infection in Phase 2 trials. These strategic moves aim to accelerate commercial readiness and clinical program advancement.LumenLumen Bioscience Expands Board and Leadership Team to Advance Clinical Pipeline of Novel Oral BiologicsLumen Bioscience announced key leadership additions to its board and executive team, including the appointment of Jeff Raikes as an independent director. These enhancements accompany a $30 million Series C financing extension led by WestRiver Group with participation from investors such as the Gates Foundation and World Wide Technology executives. The funding supports the acceleration of late-stage clinical programs for investigational oral biologics, following recent Phase 2 success for LMN-201 in treating recurrent C. difficile infection.